Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Despite a solid Q4 earnings beat, Edwards Lifesciences' shares remain undervalued with a reduced P/E multiple of 33x. Read ...

However, recent challenges in the TAVR market have led to some adjustments in price targets and expectations. Barclays (LON:BARC) Capital, which maintains an Overweight rating on the stock ...

The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with ... the News On Friday, the share price of MDT moved north 0.01% to $94.51.

The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...

The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is ...

Transcatheter aortic valve replacement (TAVR) is valve replacement without open-heart surgery. It is also called catheter-based or percutaneous (through the skin) aortic valve replacement. While ...

The SMART two-year data demonstrated that Evolut TAVR continues to show significantly less BVD, which can be a predictor of adverse outcomes, compared to SAPIEN TAVR. Additional results ...